Phio Pharmaceuticals (PHIO) Net Equity Issued and Repurchased (2013 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Net Equity Issued and Repurchased came in at $1.4 million in Q4 2024, down 43.59% YoY from $2.4 million in Q1 2024, and down 43.59% on a QoQ basis from $2.4 million in Q4 2023.
Phio Pharmaceuticals (PHIO) Net Equity Issued and Repurchased (2013 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 10 years of Net Equity Issued and Repurchased data on file, last reported at $1.4 million in Q4 2024.
- Quarterly Net Equity Issued and Repurchased fell 43.59% year-over-year to $1.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7.3 million (up 22.93% YoY) and the FY2024 annual result came in at $4.0 million, down 46.3% from the prior year.
- Net Equity Issued and Repurchased eased to $1.4 million in Q4 2024, from $2.4 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $8.6 million in Q1 2020 to a low of $1.4 million in Q4 2024.
- A 3-year average of $4.9 million and a median of $3.5 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 43.59% in 2024, down 43.59% in 2024.
- Tracing PHIO's Net Equity Issued and Repurchased over 3 years: stood at $8.6 million in 2020, then slumped by 71.92% to $2.4 million in 2023, then plunged by 43.59% to $1.4 million in 2024.
- The last three Net Equity Issued and Repurchased figures came in at $1.4 million (Q4 2024), $2.4 million (Q4 2023), and $3.5 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 2.40 Mn |
| Dec 31, 2023 | 2.40 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 3.51 Mn |
| Jun 30, 2020 | 8.56 Mn |
| Jun 30, 2020 | 8.56 Mn |
| Mar 31, 2020 | 8.56 Mn |
| Mar 31, 2020 | 8.56 Mn |
| Dec 31, 2019 | 708,000.00 |
| Dec 31, 2019 | 708,000.00 |
| Dec 31, 2018 | 5.52 Mn |
| Dec 31, 2018 | 5.52 Mn |
| Jun 30, 2018 | 4.57 Mn |
| Jun 30, 2018 | 4.57 Mn |
| Mar 31, 2018 | 932,000.00 |
| Mar 31, 2018 | 932,000.00 |
| Dec 31, 2017 | 364,000.00 |
| Dec 31, 2017 | 364,000.00 |